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. OA can affect the knees, hips, spine, and fingers, and is charac terized by progressive breakdown of articular cartilage and remodelling of the underlying bone in the synovial joints. Common clinical features include pain, joint dysfunction, and deformity. Women, older individuals, obese individuals, and individuals with prior joint inju ries all have an increased risk of developing OA, as do individuals with certain genetic and biomechanical pre disposing factors [2] [3] [4] . Current therapies for OA focus on pain control, viscosupplementation (via intraarticular injections of hyaluronic acid), and joint replacement, which all simply target the symptoms of advanced disease. Novel therapeutics are needed to inhibit the processes that drive OA pathology.
The past decade has seen a gradual but fundamental shift in our understanding of the mechanisms underlying OA. We no longer view OA as a prototypical degenerative disease resulting from normal bodily wear and tear, but rather as a multifactorial disorder in which lowgrade, chronic inflammation has a central role (BOX 1) . This inflammation comes into play early in the course of OA, as a result of interactions between the immune system and factors including local tissue damage and metabolic dysfunction 5 . Further unravelling of the mechanisms underpinning the inflammatory pathophysiology of OA is likely to yield new therapeutic approaches that can modify the course of OA.
In this Review, we examine the emerging evidence for a critical role of lowgrade inflammation in the patho genesis of OA, and discuss the current understanding of the underlying molecular mechanisms. We also explore the potential of therapeutic strategies that target this lowgrade inflammation in the prevention or treatment of OA.
OA -a whole-organ disease of the joint Traditionally, OA has been viewed as a disorder affect ing articular cartilage 2 . However, we now know that this disease affects the entire joint structure [6] [7] [8] [9] [10] . The pathologic changes that occur in OA joints are fibrilla tion and degradation of the articular cartilage, thicken ing of the subchondral bone, formation of osteophytes,
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inflammation of the synovium (synovitis), degeneration of ligaments and menisci, and hypertrophy of the joint capsule 6 (FIG. 1,2 ). Radiographic evaluation of OA bone reveals the presence of subchondral sclerosis and cysts, and microscopic examination reveals microfractures and microcracks in advanced OA 11 . Several cellular and molecular processes are involved in these pathological changes: an increase in cartilage catabolism and a concomitant decrease in cartilage anab olism and repair; hypertrophy and death of chondrocytes; impairment or dysregulation of autophagy; osteoclast mediated remodelling of bone; and infiltration and acti vation of immune cells 6 . However, many questions remain about how these processes combine to mediate the patho genesis of OA. For instance, how does the mechanical and molecular interplay between different joint tissues drive OA pathology? 6 What is the precise nature of the cross talk between the affected tissues -that is, which factors produced by one joint tissue cause pathological changes in another? In what sequence do the pathological events occur? What feedback mechanisms are involved? Answering these questions will be important for design ing nextgeneration therapeutic interventions that can prevent, slow, or reverse the development of OA.
The importance of inflammation in OA Clinically, many individuals with OA have symptoms of joint inflammation, such as morning stiffness, warmth, pain, and joint effusions that arise, in part, from syno vial thickening or synovial fluid effusion 7 . Indeed, syn ovitis, which is detectable by imaging, arthroscopy, or histology, is now recognized as a common finding in OA 7, [12] [13] [14] [15] . Histologically, this synovitis is characterized by infiltration of inflammatory cells into the synovium 16, 17 . Furthermore, molecular evidence of lowgrade inflam mation in OA is accumulating. As early as 1959 came the discovery that inflammatory plasma proteins are pres ent at abnormally high levels in both the blood and the synovial fluid of patients with OA 18 . More recent stud ies have shown that OA tissue and synovial fluid have abnormally high levels not only of plasma proteins 19 , but also of complement components 20 and cytokines 19 , and that chondrocytes and synovial cells in OA produce or overproduce many of the inflammatory mediators (for example, IL1β, TNF, and nitric oxide (NO)) 21 that are characteristic of inflammatory arthritides.
Accumulating evidence supports the association between OA pathology and different markers of inflam mation. Imaging studies involving serial MRI scans coupled with histopathologic analysis of synovial tis sues have shown that the presence of synovitis in OA is associated with an increased severity of joint symp toms, increased cartilage loss, decreased mobility, and elevated radiographic grades 12, [22] [23] [24] [25] [26] [27] [28] . Likewise, the pres ence of synovitis at the time of arthroscopy is associated with subsequent accelerated destruction of cartilage 29 .
Whether these associations reflect a causal role for inflammation in OA pathogenesis, or indicate that joint inflammation is merely an epiphenomenon in a process that is primarily degradative or mechanical, remains unclear. The timing of the inflammation, as well as mech anistic plausibility and findings from animal models genetically deficient in specific inflammatory molecules, suggests that inflammation could indeed be pivotal in the pathogenesis of OA. The presence of synovitis often predates the development of radiographic damage in OA 30 , and mononuclear cell infiltration and overexpres sion of inflammatory mediators in the synovium are prominent in early OA 31 . Likewise, elevated serum levels of Creactive protein, a marker of inflammation, are predictive of the development and progression of OA 21 . The inflammatory mediators detected in OA joints are synthesized, in part, in response to tissue injury and breakdown in the joint. They can alter chondrocyte dif ferentiation and function, as well as induce the expres sion and activation of matrix metalloproteinases (MMPs) and aggrecanases, enzymes that degrade cartilage and are thought to be the downstream effectors of OA pathogen esis 10, 16, 32, 33 . Finally, evidence from animal models suggests that inflammation contributes to joint degeneration in OA 34 , and that synovial macrophages are critical for the formation of osteophytes 35 . Thus, current evidence suggests that targeting inflammation therapeutically has the potential to prevent or reduce multiple patho logic features of OA, and thereby slow the progression of the disease.
In addition to local inflammation in the joint, sys temic inflammation might also have an important role in OA pathogenesis. For instance, obesity is known to predispose individuals to OA 36 -possibly not only by increasing the mechanical load on joints, but also by causing chronic, systemic inflammation through 37, 38 . Weight loss is associated with a substantial reduction in systemic levels of Creactive protein and IL6 in individuals with OA, and can prevent OA onset or alleviate existing OA symptoms 39, 40 . It is possible that the systemic inflamma tion associated with chronic inflammatory states, such as obesity or certain chronic diseases, promotes local inflammation in joints that ultimately results in OA.
The inflammation in OA is low-grade The inflammation observed in OA is generally chronic and lowgrade, and is believed to involve an immune response, primarily innate and to a lesser degree adap tive 41 . However, this inflammation is fundamentally different from that in rheumatoid arthritis (RA), the prototypical inflammatory arthritis. For example, the increase in levels of inflammatory plasma proteins in the blood and synovial fluid from individuals with OA (relative to healthy controls) is modest compared to that Normal OA Nature Reviews | Rheumatology in patients with RA 18, 19 . Histological comparisons reveal that inflammation is also less pronounced in typical OA synovium than in the RA synovium 14, [42] [43] [44] . These two types of inflammation differ not only in degree, but also in the cellular and molecular players involved 45 . Whereas the numbers of most immune cells (for example, macro phages and T cells) in synovial tissues are lower in OA than in RA, the number of mast cells in OA is as high as, or sometimes higher than, in RA 45 . The expression of cytokines related to macrophage or Tcell function in OA synovial tissues is also lower than in RA synovial tis sues (although higher than in normal tissue) 45 . Finally, systemically blocking the activity of conventional inflam matory cytokines with biologic therapies approved for the treatment of RA (such as antiTNF or antiIL1β ther apies) provides no benefit in generalized OA, and no or only minimal benefit in erosive OA (see below for more discussion on why these trials might have failed) 32, [46] [47] [48] [49] . Collectively, these lines of evidence suggest that the inflammatory mechanisms operating in OA differ from those in RA, and that targeting them will require novel approaches to anti inflammatory therapy.
Molecular inflammatory mechanisms in OA
In the OA joint, acute, subacute, or chronic injuries and joint tissue breakdown, often in the context of other risk factors (such as obesity, advanced age, metabolic dis orders, dysregulation of bioenergy sensors, and certain genetic factors), can trigger a progressive cycle of local tissue damage, failed tissue repair, and inflammation, resulting in further cartilage loss and progressive joint degeneration over time 10, 30, 42 . In this paradigm
3), a number of molecular components and mech anisms could transduce joint trauma, chronic injury, or overuse into inflammatory processes. These factors are discussed in the following sections.
Innate immune mechanisms
The innate immune system recognizes conserved features of pathogens via invariable patternrecognition receptors (PRRs), which comprise multiple families of cellsurface, endosomal, and cytosolic receptors. PRRs provide a first line immune response to microbial invaders. However, they recognize not only pathogenassociated molecular patterns, but also damageassociated molecular patterns (DAMPs). Produced during tissue damage, DAMPs are endogenous molecules that signal to innate immune cells (for example, macrophages and mast cells) to trigger a protective response. Once activated by DAMP-PRR sig nalling, the innate immune system produces an array of inflammatory mediators that normally initiate immune responses, and that ultimately lead to repair. However, pro longed or dysregulated activation of PRR-DAMPinduced inflammation can be destructive, and has been implicated in the chronic inflammation observed in OA 30, 50 . Like PRRs, the complement system is an innate immune mechanism by which the body recognizes path ogens 51, 52 , and has also been implicated in inflammation and damage in OA joints 53 . The complement system enhances the ability of antibodies and phagocytic cells to clear pathogens from an organism 54, 55 . Complement activation leads to chemotaxis, exudation of plasma pro teins at inflammatory sites, and opsonization of infec tious agents and damaged cells. Interestingly, several products of tissue breakdown in the joint are capable of activating both PRRs and complement [56] [57] [58] [59] [60] [61] . DAMPs. At least four classes of DAMPS are associ ated with OA (reviewed elsewhere 30 ): the products of extracellular matrix (ECM) breakdown, which occurs at sites of inflammation (such as biglycan, fibronectin, low molecularweight hyaluronic acid, and tenascin C); plasma proteins that exude from blood vessels at sites of inflammationinduced or damageinduced vascular leak age (for example, α1 microglobulin, α2 microglobulin, fibrinogen, and vitamin Dbinding protein); intracellular alarmins released from stressed, damaged, or necrotic cells (for example, HMGB1 and the S100 family of proteins); and microscopic crystals released from cartilage into the synovial space by injury or wear and tear (for exam ple, basic calcium phosphate, calcium pyrophosphate dihydrate, and uric acid).
When inducing inflammation, one of the main classes of PRRs bound by DAMPs are the Tolllike receptors (TLRs). Stimulation of TLRs ultimately leads to activation of inflammatory transcriptional programs via transcription factors such as interferonregulatory factors, nuclear factor KB (NFKB), and activator protein 1 (AP1) 42 . Among the ten functional TLRs in humans, TLR1-TLR7 and TLR9 have been detected in the synovium of individuals with OA or RA (reviewed elsewhere 15 ). TLR activation has been implicated in the development of synovitis, degeneration of cartilage, and susceptibility to disease in OA 15 , although MyD88dependent TLRs were shown to be dispensable in a mouse model of OA 62 . Indeed, in vivo studies of deficiency in DAMPs or TLRs and their agonists have generated mixed results 63 , and the effects of targeting these molecules in human OA remains to be determined (TABLE 1) . Complement system. Complement can be activated by any of three independent initiation pathways (the clas sical, alternative, and lectin pathways), which all subse quently converge on complement components C3 and C5, resulting in the formation of C3 and C5 convertases, respectively. Activation of these convertases induces the generation of the effector components of the comple ment cascade: the C3a and C5a anaphylatoxins promote inflammation by chemoattracting proinflammatory leu kocytes, and the membrane attack complex (MAC) pro motes tissue damage and inflammation. The MAC binds to the outer surface of cell membranes, and can form a transmembrane pore that results in cell lysis 64, 65 . When bound to a cell surface at sublytic levels, however, the MAC instead induces proinflammatory cell signalling, such as that mediated by mitogenactivated protein kinases, the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, and NFKB 66 . Evidence from both human and mouse studies sug gests the complement system has a central role in the pathogenesis of OA 53 . Decades ago, several reports described complement and immunoglobulin deposits in OA cartilage 67 and synovium 68 , and complement compo nents have since been shown to be produced, in part, by chondrocytes 69 . In 2011, our group reported that OA syn ovium expresses higher levels of complement effectors and lower levels of complement inhibitors than healthy synovium 53 . DAMPs present in OA joints, such as car tilage ECM proteins, calcium crystals, and components of apoptotic debris, also bind and activate comple ment 5661 . Findings from mouse studies suggest that this overproduction and hyperactivation of complement in the joint has an important role in OA pathology: defi ciency in the complement components C5 or C6 atten uated experimental OA, whereas deficiency in CD59a (a protein that inhibits MAC formation, and hence also MAC activity 70 ) worsened it 53 . Still unknown, however, is whether complement deposition in OA joints is itself a triggering event or whether it is secondary to low grade inflammation or to the damage of cartilage or joint tissues. These findings suggest that strategies that block complement activation have therapeutic potential for OA, but whether chronic inhibition of complement would be required and what adverse effects this inhibition might have are unclear.
Carboxypeptidase B. Evidence from both human and mouse studies suggests that the enzyme carboxypeptidase B (CPB) protects against the inflammatory destruction of OA joints by inhibiting proinflammatory anaphylatoxins and effectors of the complement system 71 . Produced pri marily by the liver as a circulating plasma zymogen, CPB is activated by the thrombin-thrombomodulin complex during thrombotic events. In the joint, thrombomodulin expressed by synovial lining cells 72, 73 and neutrophils 74 forms a 1:1 complex with thrombin, and activates pro carboxypeptidase B (also called thrombinactivatable fibrinolysis inhibitor), resulting in the generation of CPB. By cleaving its substrates' Cterminal arginine or lysine, CPB can in turn inactivate several inflamma tory proteins, such as fibrin, C5a, C3a, bradykinin, and thrombincleaved osteopontin 75, 76 , and thereby protect the joints from inflammatory destruction 71 . Whether treatments that target CPB have protective effects in OA clinical trials remains to be determined.
Macrophages and mast cells. Innate immune cells that can be activated by DAMPs and complement include macrophages and mast cells 77, 78 , both of which are implicated in OA pathogenesis. Macrophages in the synovium of OA joints are activated and contribute to cartilage breakdown and osteophytosis by producing cytokines, such as IL1β and lymphotoxinα, as well as proMMPs 17, 35, 79, 80 . Activated mast cells are also present in OA synovial tissues, and higher numbers of mast cells in OA synovial tissues are associated with a greater degree of both synovitis and structural damage in the synovial joints 45 . The mechanisms by which macro phages are activated in the OA joint and contribute to the pathogenesis of OA are currently under investigation.
Mast cells are a heterogeneous group of cells that can be subdivided into those containing only tryptase and those containing both tryptase and chymase 81 . The increase in number of mast cells in OA synovial tis sue (compared with their numbers in normal tissue) is attributable to the selective expansion of the tryptase only population of mast cells, in contrast to the expan sion of both mast cell populations that occurs in RA 82, 83 . Furthermore, tryptase activity is higher in mast cells in OA synovial tissues than in normal synovial tissues 84 ; mast cell tryptase released into the synovial fluid stim ulates the proliferation of fibroblastlike cells and the production of proinflammatory cytokines by these cells 84 , and could in this way contribute to OA pathol ogy. Another classic mast cell mediator is histamine. Compared with those in RA, mast cells in OA synovial tissues have similar or higher histamine content 85 , but lower histamine release 86, 87 . The exact roles of mast cells and their mediators in OA remain poorly understood.
Adaptive immune mechanisms
Levels of antibodies and immune complexes are abnor mally high in OA synovial fluid and joint tissues, although the specificities of the antibodies involved and the relevance of these increases in antibody levels are unclear 20, 67, 88 . It is possible that the cartilage and cellular debris released during cartilage degeneration exposes . Further investigation is needed to define the role of antibodies and of the adaptive immune response in the pathogenesis of OA.
Inflammatory mediators
As mentioned earlier, various soluble inflammatory mediators have been identified in OA joint tissues and fluids, including cytokines, chemokines, growth factors, adipokines, prostaglandins and leukotrienes, and regula tors such as CPB (reviewed elsewhere 30 ). These mediators can be produced by different cell types within the joint, including fibroblastlike synoviocytes, chondrocytes, and resident or infiltrating immune cells 15, 90 .
Cytokines. Cytokines are among the most extensively studied mediators of inflammation. Several cytokines, such as TNF, IL1β, IL6, IL15, IL17, IL18, IL21, and leukaemia inhibitory factor, have been implicated in the pathogenesis of OA 30, 90 . The precise contributions of different cytokines to OA remains to be elucidated, but inflammatory cytokines have been proposed to induce cartilage catabolism as well as inhibit anabolic processes that are critical to cartilage homeostasis 30, 91, 92 . For example, IL1β and TNF signalling mediated by the transcription factors NFKB and AP1 results in auto crine production of these cytokines, as well as expres sion of other inflammatory and chrondrolytic mediators (including NO, prostaglandin E2 (PGE2), IL6, MMP1, MMP9, and MMP13), in OA cartilage ex vivo 93 . Despite encouraging results from animal studies, antiIL1β and antiTNF therapies have not yielded positive results in OA clinical trials 4649 . The disappointing results from human trials suggest that targeting a single cytokine (such as IL1β or TNF) at the systemic level might not be sufficient to have a beneficial effect on OA; unlike RA, in which TNF drives IL1β production, IL1β and TNF could act in a parallel, redundant manner in OA 32 . Failure of these anticytokine therapies might also be explained by the inability of systemically administered anticytokine therapeutics to penetrate the joints, or by the evaluation of their efficacy in latestage OA when the disease process might be lessresponsive to such therapies, or by other factors 32 . Likewise, trials of MMPblocking therapies in humans have shown a discouraging lack of efficacy and/or unacceptable toxicity [94] [95] [96] . Other cytokines could also be targeted therapeutically, but selecting which cytokine to target in OA will require a thorough understanding of the underlying mechanisms 90 .
Chemokines. Many chemokines (a subset of cytokines that induce the recruitment and trafficking of inflamma tory cells and mesenchymal progenitors) are produced within the OA joint 15, 97, 98 . Certain chemokines and their receptors (IL8, CCL5, CCL19, CCR1, CCR2, CCR3, and CCR5, among others) might facilitate the onset and progression of OA 15 , not only by inducing the release of MMP3 by chondrocytes and hence the breakdown of cartilage matrix components 99 , but also by promot ing osteoclastmediated remodelling of periarticular bone. Other chemokines might be protective in OA: Tenascin C Tnc -/-mice showed resolution of acute joint inflammation and were protected from sustained and erosive joint inflammation; intra-articular injection of tenascin C promoted inflammation 169 Not tested S100A8, S100A9
S100A9
-/-mice (also lacking S100A8 at protein level) showed reduced synovial activation, osteophyte formation, and OA cartilage destruction 170, 171 Not tested C5 C5 -mice showed less cartilage loss, osteophyte formation, and synovitis; treatment with an anti-C5 monoclonal antibody or CR2-fH (a fusion protein that inhibits C3 and C5) attenuated OA Celecoxib and rofecoxib (COX2 inhibitors) were associated with cardiovascular toxicity and other adverse effects [180] [181] [182] [183] Etoricoxib (a COX2 inhibitor) inhibited acute inflammation and adjuvant-induced arthritis 184 Etoricoxib improved symptoms of OA 185, 186 COX1, COX2
Naproxen (a non-selective COX inhibitor) suppressed MMP activities and the decrease in proteoglycan content 187 Naproxen improved pain associated with knee OA more than hip OA , but was associated with acute liver injuries 195 Bradykinin Icatibant (a bradykinin B 2 receptor antagonist) reduced inflammation 149 Icatibant showed an analgesic effect on knee OA 149 , but no detectable anti-inflammatory effects 150 
CPB
Cpb2 −/− mice showed more severe cartilage damage, osteophyte formation, and synovitis 71 Not tested NO, iNOS L-NMMA (a broad NOS inhibitor) reduced synovial inflammation and tissue damage in animal models of arthritis [196] [197] [198] ; S-methylisothiourea attenuated MIA-induced pain and histopathological changes in the knee joint 199 Cindunistat (an iNOS inhibitor) failed to slow progression of OA 147 
MMPs
MMP inhibitors prevented the destruction of articular cartilage and bone [200] [201] [202] [203] [204] PG-116800 (an MMP inhibitor) failed to show benefit and was associated with the development of musculoskeletal toxicity 94 
IL-1β, MMPs
Strontium ranelate reduced the progression of OA structural changes 165 Strontium ranelate showed disease-modifying effects 163 5LO, arachidonate 5-lipoxygenase; COX, cyclooxygenase; CPB, carboxypeptidase B; DMOAD, disease-modifying OA drug; FGF18, fibroblast growth factor 18; LTB4, leukotriene B4; iNOS, inducible NO synthase; L-NMMA, N G -monomethyl-L-arginine; MIA, monosodium iodoacetate; MMPs, matrix metalloproteinase; NGF, nerve growth factor; NO, nitric oxide; NOS, NO synthase; OA, osteoarthritis; scFv, single-chain variable fragment.
for instance, stromal cellderived factor1 (also called CXCL12) recruits mesenchymal progenitors and thereby promotes tissue repair 100 . Yet other chemokines could have a dual role in inflammation, depending on the context in which they are produced 101 .
Growth factors. Growth factors such as transforming growth factorβ (TGFβ), fibroblast growth factors (FGFs), vascular endothelial growth factor (VEGF), and nerve growth factor (NGF) have been implicated in OA. The TGFβ family of growth factors is broadly expressed in cartilage, bone, and synovial tissues 102 . TGFβ growth factors are normally crucial for maintaining cartilage homeostasis but have been linked to the promotion of osteophytosis and synovial fibrosis in OA 35, 42, 103 . Three members of the FGF family expressed in articular car tilage, namely FGF2, FGF8, and FGF18, are involved in cartilage homeostasis and might be associated with OA 104 . VEGF, generated by the inflamed synovium, can promote angiogenesis and thereby facilitate infiltration of the joint by immune cells that contribute to inflam mation in OA 105 . NGF regulates monocyte inflammatory responses and the production of IL1β, TNF, IL6, and IL8 via the highaffinity NGF receptor (also known as tyrosine kinase receptorA (TrkA)) 106 . Inhibiting NGF with monoclonal antibodies, including tanezumab and fulranumab, significantly reduced pain in individuals with OA 107 . Therapeutic approaches that target growth factors hold promise for preserving cartilage or stimulating its repair 108 . Several therapies that inhibit VEGF have proven beneficial in animal models of arthritis, and their antiinflammatory and antiangiogenic effects in OA are now being evaluated in clinical trials 109 . Intra articular administration of recombinant FGF18 is also being investigated in individuals with OA (TABLE 1) . However, local growth factor therapy risks promoting osteochondral bone formation, especially osteophyte outgrowth, whereas systemic diffusion of the growth factor might induce growth in normal tissues or, even worse, in premalignant lesions 32 .
Adipokines. High systemic and synovial fluid levels of adipokines, a family of cytokines secreted primarily by adipose tissue, are associated with cartilage degenera tion and synovial inflammation in OA [110] [111] [112] . Thus, an increase in adipokine levels might explain why obe sity (in which altered biomechanics could also have a role) and other features of the metabolic syndrome (hypertension, dyslipidaemia, insulin resistance, and others) increase the risk of developing OA 36, 111, 113, 114 . Several adipokines, such as leptin, adiponectin, resis tin, visfatin, and nefastin1, have contextdependent immunomodulatory properties 115, 116 and can induce the production of inflammatory mediators and carti lagedegrading factors, leading to chondrocyte degra dation and the development of OA 112, 115, [117] [118] [119] [120] [121] [122] [123] [124] . Visfatin, for instance, the expression or enzyme activity level of which is regulated by IL1β, hypoxiainducible factor 2α (HIF2α), and other interleukins, not only inhibits the phosphorylation of insulin receptor factors such as IRS1 and AKT, thus reducing proteoglycan production, but also increases the expression of MMPs, NGF, and PGE2, thereby aggravating OA 120 . Adipokines are also produced in the OA joint by infrapatellar fat pads, syn ovium, chondrocytes, osteoblasts, and osteoclasts 125, 126 , which could additionally serve as local sources of other inflammatory mediators in the joint, such as neuro peptides and the classic inflammatory cytokines IL1β, IL6, and TNF 30 . Prevention of metabolic syndrome by lifestyle changes might relieve OA symptoms through reductions in adipokine levels and, in the case of weight loss, reduction in joint biomechanical stress.
Prostaglandins and leukotrienes. Lipid mediators, including prostaglandins and leukotrienes, have been detected in the OA joint and might be involved in the pathogenesis of OA 19, 127, 128 . In particular, PGE2 is likely to contribute to OA pathology by promoting inflam mation, apoptosis, and angiogenesis 127 , whereas leu kotriene B4 (LTB4) might act as a powerful leukocyte chemo attractant 129 and could stimulate the production of IL1β and TNF by synovial tissues 130 . Substantial efforts have been made to elucidate the mechanisms governing prostaglandin and leukotriene production in OA, with a view to their therapeutic target ing. Prostaglandins and leukotrienes are generated from arachidonic acid via distinct enzymatic cascades that can be induced by inflammation or trauma 127, 128, 131 , such as that occurring in OA. Prostaglandins are produced by the cyclooxygenase pathway, in which cyclooxygenase2 (COX2, also known as prostaglandin G/H synthase2) is the ratelimiting enzyme mediating inducible prosta glandin production. COX2 is overexpressed in inflamed articular tissues 127 , and its expression in human chon drocytes can be induced by pro inflammatory cytokines (IL1β, TNF, IL6, and others), as well as by TLR4 stim ulation 132 . Likewise, prostaglandin E synthase, the key terminal enzyme in the production of PGE2, is over expressed in OA cartilage 133 , and its expression in human OA chondrocytes can be induced by IL1β and TNF 134, 135 . Moreover, prostaglandin E synthase localizes to the superficial layers of human OA cartilage, which is where OA damage first occurs 133 . Upregulation of leukotriene production is also evident in OA joints. Arachidonic acid released from cell membranes in the OA synovial tissues, synovial fluid, cartilage, and subchondral bone 128, 136 can also be converted to the unstable precursor leukotriene A4 (LTA4) via arachidonate 5lipoxygenase (5LO) and 5LOactivating proteins, with LTA4 in turn being converted to LTB4 by LTA4 hydrolase 131 . NSAIDs and other COX2 inhibitors reduce prosta glandin production and inflammation in OA, but serve only to attenuate pain and are associated with a broad spectrum of adverse effects on the liver, kidney, car diovascular system, gastrointestinal tract, and skin 137 . Several agents that inhibit both COX2 and COX1 (cyclooxygenase1, also known as prostaglandin G/H synthase1) enzymes as well as 5LO are currently in development as inhibitors of bioactive leukotriene gen eration, and their safety and efficacy in OA are being evaluated in clinical trials 138 (TABLE 1) .
Nitric oxide. NO might also be involved in inflam matory processes in OA 139, 140 . Cytokines such as those prevalent in OA joints induce the expression of NO via the inducible NO synthase (iNOS) pathway 141 , and iNOS mRNA and protein have been found in the synovium of individuals with OA 142 . Indeed, high lev els of nitrite have been detected in arthritic synovial fluid and serum 143 , consistent with the observation that NO production is abnormally high in OA car tilage 144 . NO has been proposed to contribute to the cartilage destruction in OA by enhancing expression of MMPs, inhibiting collagen and proteoglycan syn thesis, and inducing apoptosis (in a process involving COX2mediated production of PGE2) 145, 146 . However, NO has also been proposed to have protective effects in OA by inhibiting the activation of proinflammatory pathways 140 . Although in vivo experiments in animal models suggest that inhibiting NO or iNOS could be an attractive avenue for treating OA 32 , the selective iNOS inhibitor cindunistat failed to slow the progression of OA in clinical trials 147 (TABLE 1) .
Neuropeptides. In the OA joint, neuropeptides have an active role not only in pain modulation, but also in the initiation and perpetuation of inflammation (by activating infiltrating inflammatory cells and by induc ing production of proinflammatory cytokines) 7, 148 . Examples of such proinflammatory neuropeptides include substance P, bradykinin, corticotropin releasing factor, urocortin, and vasoactive intestinal peptide 7, 148 . In OA, substance P is present in the subin timal portion of the synovium and in areas containing osteophytes or cartilage erosions, and can contribute to the inflammatory response by activating immune cells, stimulating the release of cytokines (such as IL1β and TNF), inducing synoviocytes to proliferate and pro duce PGE2 and collagenase, and increasing osteoclast formation and synovial hypertrophy 148 . Bradykinin in the OA synovium can contribute to the initia tion and maintenance of inflammation by activating synoviocytes and chondrocytes and possibly by syn ergistically potentiating the proinflammatory effects of cytokines 149 . However, intraarticular administration of the specific bradykinin B2 receptor antagonist icatibant in individuals with knee OA had a longlasting analge sic effect 149 but no detectable anti inflammatory effect, as assessed by ultrasonography or MRI 150 (TABLE 1) .
Circadian clock dysregulation
Disruption of the circadian rhythm could be another mechanism by which chronic inflammation contrib utes to OA pathogenesis. Findings published in 2016 indicated a role for the circadian clock component aryl hydrocarbon receptor nuclear translocatorlike pro tein1 (also known as brain and muscle Arntlike protein1 (BMAL1)), which is downregulated in OA cartilage, in maintaining homeostasis and integrity of cartilage tissue 151 . Indeed, environmental disruption of their circadian rhythms predisposes mice to OAlike damage of their knee cartilage 152 , and autonomous cir cadian rhythms in cartilage become dysregulated with age and with chronic inflammation, as well as in mouse models of injuryinduced OA [153] [154] [155] [156] . Interestingly, a local circadian clock in pulmonary epithelial cells controls neutrophil recruitment to the lungs in response to local bacterial stimuli 157 , which could explain the diurnal variation in symptom severity of inflammatory lung diseases. Weakening of the local circadian clock in car tilage (and possibly in other joint tissues as well) might likewise contribute to the circadian variation seen in OA symptoms. Disruption of the cartilage circadian clock could conceivably both result from and contrib ute to inflammation in OA. In such a scenario, a vicious cycle operates in which chronic inflammation weak ens the cartilage circadian clock, leading not only to a decrease in expression of proteins involved in cartilage anabolism 151 , and hence to cartilage loss, but also to an increase in expression of inflammatory cytokines 151 , and hence to the propagation of inflammation in the joints. Furthermore, circadian rhythms intrinsic to immune cells affect cytokine responses and immune cell traf ficking 158, 159 and, therefore, dysregulation of the immune cell clock could potentially contribute to inflammation in OA.
Anti-inflammatory therapeutics for OA Given the critical role of lowgrade inflammation in OA, novel antiinflammatory therapeutics could offer new opportunities for treating this disease. Although lifestyle changes involving exercise and/or dietinduced weight loss are simple and (in some individuals) effec tive 139 ways of slowing the progression of OA, such reg imens are difficult to implement in individuals with OA who are elderly or have limited mobility. Currently, only symptommodifying agents, such as analgesics, NSAIDs, steroids, and hyaluronic acid, have been approved as therapeutic interventions for OA; that is, until joint replacement is needed 139, [160] [161] [162] . None of the approved treatments can restore the original structure and function of damaged joints, nor can they slow the progression of OA. Moreover, these medications fre quently have deleterious adverse effects. A substantial need remains for safe and effective diseasemodifying OA drugs (DMOADs).
Inhibition of the lowgrade inflammation in OA could form the basis of such muchneeded DMOADs (FIG. 4) . Because inflammation is present early in the course of OA, before structural changes have occurred 30 , therapeutic strategies targeting the lowgrade inflam matory processes might be able to not only halt the progression of OA, but also prevent the onset of radio graphic OA. Several antiinflammatory therapeutics have been tested in human OA, but the results have thus far been disappointing 139, [160] [161] [162] . Findings from the SEKOIA study suggest that strontium ranelate has diseasemodifying effects in individuals with knee OA 163, 164 , possibly through antiinflammatory mech anisms involving inhibition of IL1β 165 and MMP 166 production. Nonetheless, whether the benefits pro vided by strontium ranelate can actually prevent or delay joint replacement, and whether individuals with OA will be compliant in taking this drug (which has 164, 167 ) remains unclear. Several promising findings showing diseasemodifying effects of inhibitors of lowgrade inflammation in ani mal models of OA warrant followup in human clinical trials (TABLE 1) .
Because of the heterogeneity of OA, the large num ber of diverse molecules involved in its pathogenesis, and the multifaceted roles of these molecules under normal or pathologic conditions, effective treatment of OA might require a combination of approaches. Furthermore, teasing apart the precise roles of certain inflammatory components in different contexts will also be important, as targeting these components might not be feasible if they also have protective functions in tissue repair. That is, as we have learned from failed attempts at targeting IL1β [46] [47] [48] and MMPs 94 , antiinflammatory therapies for OA will likely have to be broad enough to be effective, but selective enough to avoid deleterious offtarget effects. Ongoing advances in imaging tech nologies and biomarker development should facilitate the testing of candidate therapies by enabling anti inflammatory interventions early in the course of OA -when they could be most effective -through earlier diagnosis and better stratification of patients, as well as earlier and more accurate assessment of clinical response to novel therapeutics.
Conclusions
Although the evidence supporting a role of chronic, lowgrade inflammation in OA is wellestablished, only recently have we begun to appreciate that this inflam mation has a pivotal role in the pathogenesis of OA. A further shift in our understanding has come with the realization that OA is a disease of the whole joint, affect ing not only the articular cartilage, but also the syn ovium, tendons, muscles, ligaments, subchondral bone, and adipose tissue; perhaps it is even a systemic disease, with inflammation having a critical role in the interplay between the joint tissues. The complexity of the inflam matory mechanisms in OA pathophysiology is becom ing apparent. Future work is needed to fully define the molecular pathways mediating the lowgrade inflam mation in OA, and to use this information either to repurpose existing drugs or candidate therapeutics that target these pathways, or to develop nextgeneration therapeutics. Ultimately, clinical trials are needed to determine whether targeting lowgrade inflammation can indeed prevent or slow the development and progression of human OA. Examples of risk factors for OA, cell types involved in its pathogenesis, and molecular components in the inflammatory pathways that are potential therapeutic targets for preventing or treating OA are shown. CPB, carboxypeptidase B; DAMPs, disease-associated molecular patterns; NO, nitric oxide; OA, osteoarthritis.
